QIAGEN’s QIAxcel Connect wins Red Dot design award

International design competition recognizes high-resolution DNA or RNA capillary electrophoresis instrument // QIAxcel marks the fourth QIAGEN instrument to receive Red Dot award, highlights strategy of upgrading portfolio to add new features – in particular wireless connectivity // QIAxcel Connect offers scientists many benefits for nucleic acid analysis with minimal handling time, flexible throughput and speed

Venlo, the Netherlands, March 29, 2023 (GLOBE NEWSWIRE) — QIAGEN today announced that QIAxcel Connect, its high-resolution gel electrophoresis instrument for use with DNA or RNA samples, has won the prestigious Red Dot award. This marks the fourth instrument from QIAGEN to receive this award from one of the most important design competitions.

QIAxcel Connect automates what was traditionally a laborious laboratory task: to analyze the size and quality of isolated DNA and RNA. It combines ease of use, high capability, flexible throughput and economy in a single instrument. Scientists just insert a cartridge – cleverly designed to include everything needed – and then add their samples. The system automatically performs the analysis. Real-time results display on a connected computer, and the run status can be monitored anywhere via a secured cloud connection. 

“We are pleased to have the Red Dot jury recognize the innovative product design of the QIAxcel Connect instrument,” said Thomas Schweins, Senior Vice President and Head of QIAGEN’s Life Sciences Business Area. “Coming after the Red Dot award for the EZ2 Connect instrument in 2022, we see it as endorsement of the strategy to update our instrument portfolio and to integrate greater digital connectivity.”

QIAxcel Connect provides options for customization to suit individual needs. Scientists benefit from minimal handling time, flexible throughput, and the speed of the system. Compared to other electrophoresis instruments, QIAxcel Connect is also viewed as offering greater convenience due to its simple set-up, greater flexibility and low running costs. It also provides high analytical power, with many applications addressed. 

Scientists can use QIAxcel Connect for a broad range of laboratory application areas, including food and microbial testing, academic research, or disease and therapeutic research. QIAxcel Connect is highly suited for analysis and quality control of next-generation sequencing (NGS) libraries, as well as low-concentration samples (such as liquid biopsies), degraded samples (such as formalin-fixed paraffin-embedded tissues), and multiplex PCR products with high-resolution requirements.

To learn more about QIAxcel Connect, visit our website.



QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective workflows. QIAGEN provides solutions to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare), Applied Testing (primarily forensics), Pharma (pharma and biotech companies) and Academia (life sciences research). As of December 31, 2022, QIAGEN employed approximately 6,200 people in over 35 locations worldwide. Further information can be found at http://www.qiagen.com.

Forward-Looking Statement

Certain statements contained in this press release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. To the extent that any of the statements contained herein relating to QIAGEN’s products, collaborations markets, strategy or operating results, including without limitation its expected adjusted net sales and adjusted diluted earnings results, are forward-looking, such statements are based on current expectations and assumptions that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with management of growth and international operations (including the effects of currency fluctuations, regulatory processes and dependence on logistics), variability of operating results and allocations between customer classes, the commercial development of markets for our products to customers in academia, pharma, applied testing and molecular diagnostics; changing relationships with customers, suppliers and strategic partners; competition; rapid or unexpected changes in technologies; fluctuations in demand for QIAGEN’s products (including fluctuations due to general economic conditions, the level and timing of customers’ funding, budgets and other factors); our ability to obtain regulatory approval of our products; difficulties in successfully adapting QIAGEN’s products to integrated solutions and producing such products; the ability of QIAGEN to identify and develop new products and to differentiate and protect our products from competitors’ products; market acceptance of QIAGEN’s new products and the integration of acquired technologies and businesses. For further information, please refer to the discussions in reports that QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission (SEC).


CONTACT: John Gilardi
+49 2103 29 11711

Phoebe Loh
+49 2103 29 11457

Thomas Theuringer
+49 2103 29 11826

Daniela Eltrop
+49 2103 29 11676

error: Content is protected !!